Medications for Your Heart & Kidney | Dr. Curnew MD
In this video, our medication team members will be teaching us
about RAS inhibitors, Aldosterone blockers, and SGLT2 receptor
antagonists! These medications are the three pillars for protecting
your kidney. In this video, you will learn more about these three
important medications.
Timestamps:
00:00 Intro
00:15 Heart & lungs
00:32 How are heart & kidney disease related?
01:27 Renin-Angiotensin Inhibitor Medications
01:44 ACE & ARB Inhibitor Medications
02:02 Common ACE inhibitors
02:15 Common ARB (angiotensin II receptor blocker)
02:26 Trials on ACE inhibitors
03:03 Trials on ARB meds
03:51 Aldosterone receptor blockers or mineralocorticoid receptor antagonists (MRAs)
04:02 Spirinolactone vs Finerenone
05:47 SGLT2 Inhibitors
07:38 Our other videos
References:
1. British Heart Foundation, The Heart Kidney Link, Heart Matters, n.d.
2. National Kidney Foundation, The Heart and Kidney Connection, n.d.
3. Mukoyama et al., Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?, Hypertension Research, 2022.
4. National Kidney Foundation, ACE Inhibitors and ARBs n.d.
5. Hou et al., Efficacy and safety of benazepril for advanced chronic renal insufficiency, N Engl J Med, 2006.
6. Edmund et al., Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes, N Engl J Med, 2001.
7. Pfizer, Aldactone Clinical Pharmacology, Pfizer Medical Information, n.d.
8. Marcath, Finerenone, Clinical Diabetes, 2021.
9. Piko et al., Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease, Pharmaceuticals, 2024.
10. Pitt et al., The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure, New England Journal of Medicine, 1999.
11. American College of Cardiology, Randomized Aldactone Evaluation Study - RALES, American College of Cardiology, 2002.
12. Bakris et al., Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes, New England Journal of Medicine, 2020.
13. National Kidney Foundation, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, National Kidney Foundation, n.d.
14. Perkovic, Cardio-Kidney-Metabolic disease: clinical trials and tribulations [webinar], David Braley Research Institute, 2024.
15. Patel et al., Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis, Circulation, 2024.
💻Check out our NEW Website: https://www.drcurnewhealth.com
💌 Sign up for our weekly newsletters: https://forms.gle/RQWv9QMckWzM2g6W8
Thanks for checking our videos out!
Social Media:
Facebook ➡️ @drcurnew
Twitter ➡️ @DrGregCurnew
Instagram ➡️ @drcurnew
#kidneys #ckd #chronickidneydisease #egfr #heartfailure #congestiveheartfailure #chf #proteinuria #albumin #albuminuria #hearthealth #medications #cardiovasculardisease #cardiology #healthylifestyle #cardiovascularhealth #heartdisease #behealthy
